In this study, we focused on the evaluation of alterations in the expression of the HGF-MET axis in ESCC, one of the spotlight targets for gastrointestinal (GI) cancer, due to its overexpression in 10 to 70% of different GI tumors (20, –22). This evidence concerns the gene HGF and digestive system neoplasm.